Athyrium Capital Management, LP
New York, NY · CIK 1728001 · 13F filing filed 2024-11-12
SEC-registered investment adviser since 2012 · limited partnership
- Assets managed$2.5bn
- Staff20 · 11 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds8 (7 hedge) · $2.5bn gross assets
- Websiteathyrium.com
- Form ADV · 2026-09-08SEC adviser record
- Kindhedge funds, private equity, futures
- Others nearbyNew York, NY
As an employer
- Offices in1 country
- Private fundshedge 7, private equity 1
$8.7m
reported value
-74.1% vs Q2 2024
2positions
100.0%in top 10
0 new
0 added
0 reduced
1 sold out
vs Q2 2024
Holdings, Q3 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| BIORA THERAPEUTICS INC COM NEW | $5.5m63.12% | Unchanged |
| PUMA BIOTECHNOLOGY INC PBYI | $3.2m36.88% | Unchanged |
Sold out since Q2 2024
| Security | Value then |
|---|---|
| COHERUS BIOSCIENCES INC CHRS 1.5 04.15.26 | $22.2m30.0m shares |